Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

This study is looking at factors that predict how well CAR-T cell therapy — a type of treatment that engineers a patient's own immune cells to attack cancer — works in people with large B-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. **You may be eligible if...** - You have been confirmed to have large B-cell lymphoma - Your lymphoma has come back or stopped responding after at least two previous rounds of standard treatment - You are planning to receive an approved CAR-T cell therapy product **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have poor ability to follow through with the study - Your doctor determines another condition makes participation unsuitable Talk to your doctor to see if this trial is right for you.